Stock Analysis

Moderna Inc (MRNA:NASDAQ)

7 Nov 2020
Moderna Inc. operates as a clinical stage biotechnology firm.
Key Statistics
52-Week Range Avg. Daily Vol (3 Mo) Market Value Dividend Yield Float % Target Price Consensus Rating
(5 strong buy – 1 strong sell)
Next Earnings Announcement
17.68 – 95.21 9,669,706 32,622.3 81.8% 95.00 4.50 26/02/2021


The company focuses on the discovery and development of messenger RNA therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immune-oncology and cardiovascular diseases. mRNA provides real-time instructions within the body to make proteins that drive human biology, including health and disease.

The share price has surged during the COVID-19 pandemic on the assumption of its successful vaccine mRNA-1273, in addition to other pipeline therapies. Following the success of Pfizer’s vaccine trial that prevented COVID-19 in 90% of clinical trial patients, Moderna’s first interim data is likely to be announced in November and report full-efficacy results by the end of 2020. Moderna also has a pipeline of other vaccines in development including it’s most advanced pipeline asset mRNA-1647 for the prevention of cytomegalovirus (CMV), part of the herpes virus that causes cold sores and chickenpox. Additional vaccines including mRNA-1653 which combines antigens for human metapneumovirus (hMPV) and parainfluenza virus 3 (PIV3), both of which cause upper and lower respiratory disease that can progress to bronchitis or pneumonia.

Revenue is predicted to rise 549.3% in the financial year ended December 2020 from $60.2 in 2019 and a further 819% in 2021 to $3,593.3. Despite stronger revenue in 2020, adjusted earnings per share is expected to decline -5.1% to -$1.63 before rising 268% in 2021 to $2.74. While forecast to have negative earnings per share in 2020, the forecast growth would see the stock trade on a forward P/E multiple of 30.1 for 2021, a 57% premium compared to an average of 20.3 of peers.

The average target price of analysts covering the stock is $95 with 81% of analysts rating the stock as a buy, compared to 6% as a sell and 13% as a hold.



You need to be a Premium user to comment on this post. Click here and become premium now!

We are glad you liked it

For your convenience, this will appear under your Saved articles in the top menu.